bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
0.5297
-0.0001 (-0.02%)
At close: Aug 6, 2026, 4:00 PM EDT
0.5301
+0.0004 (0.08%)
Pre-market: Aug 7, 2026, 4:50 AM EDT
bioAffinity Technologies Revenue
bioAffinity Technologies had revenue of $1.35M in the quarter ending March 31, 2026, a decrease of -27.09%. This brings the company's revenue in the last twelve months to $5.66M, down -35.75% year-over-year. In the year 2025, bioAffinity Technologies had annual revenue of $6.16M, down -34.18%.
Revenue (ttm)
$5.66M
Revenue Growth
-35.75%
P/S Ratio
0.42
Revenue / Employee
$99,296
Employees
57
Market Cap
2.40M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.16M | -3.20M | -34.18% |
| Dec 31, 2024 | 9.36M | 6.83M | 269.68% |
| Dec 31, 2023 | 2.53M | 2.53M | 52,627.44% |
| Dec 31, 2022 | 4.80K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MDxHealth | 110.97M |
| Burning Rock Biotech | 74.58M |
| Exagen | 71.12M |
| XWELL | 28.83M |
| Precipio | 25.83M |
| Insight Molecular Diagnostics | 1.95M |
| iSpecimen | 1.03M |
| Quantum Cyber | 537.08K |
BIAF News
- 10 days ago - BioAffinity announces publication of clinical review on CyPath Lung - TheFly
- 10 days ago - bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung - Business Wire
- 15 days ago - BioAffinity Technologies announces collaboration with Pictor - TheFly
- 15 days ago - bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD - Business Wire
- 4 weeks ago - BioAffinity Technologies’ CyPath Lung diagnostic sales double in Q2 - TheFly
- 4 weeks ago - bioAffinity Technologies' Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues - Business Wire
- 6 weeks ago - BioAffinity will present preclinical findings on small interfering RNAs - TheFly
- 6 weeks ago - bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells - Business Wire